Haryana Goes Big on Pharma: New Policy Targets ₹10K Cr Investment

The Haryana government is set to roll out its Pharmaceutical and Medical Devices Manufacturing Policy, an ambitious framework designed to attract investments worth ₹10,000 crore and create at least 20,000 jobs over the next five years. Developed by the Department of Industries and Commerce, the policy positions the state as a premier manufacturing destination for medicines, bulk drugs, and high-end healthcare products.

Beyond local economic growth, the policy directly supports India’s Atmanirbhar Bharat (self-reliance) goals by aiming to drastically reduce reliance on imports for critical inputs like Active Pharmaceutical Ingredients (APIs). To drive this transformation, Haryana is introducing a powerful mix of financial backstops—including up to 30% in CAPEX subsidies and 80% in OPEX subventions—alongside comprehensive support for R&D, green manufacturing, and streamlined regulatory processes.

Amit Kumar Agrawal, IAS, Commissioner & Secretary of the Industries and Commerce Department, highlighted that the policy will significantly improve the ease of doing business and foster an innovation-driven ecosystem. This timely state intervention aligns with projections showing India’s pharmaceutical sector expanding toward $130 billion by 2030, while actively fortifying domestic healthcare supply chains against global vulnerabilities.

News by Rahul Yelligetti.